The firm argues GLP-1 wins proved peptides work as a drug platform, covering oral macrocycles and AI-driven discovery.
Recap by typeshit. Post by Water Tower Research LLC on X.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
A local feature on clinics in Sarasota using peptides for recovery, hormones and wellness. The claims come from the practitioners and are not backed by cited evidence.
Halioua argues dogs beat mice as models because they are genetically diverse, share our environment and develop age-related diseases naturally. No peptide link is stated.
Loading…